Emalex Biosciences

About Emalex Biosciences

Emalex Biosciences is a Chicago-based biotechnology company focused on developing new treatments for central nervous system disorders, with an emphasis on Tourette syndrome. The company is advancing a first-in-class drug, ecopipam, through late-stage clinical trials and expanding patient access through programs like Expanded Access in the United States. Emalex emphasizes relief from tics and related social and emotional impacts, aiming to provide options for patients with limited treatments. The organization collaborates with regulatory bodies and engages in research and development to bring CNS-focused therapeutics to market.